Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
  • Page of 1
Wagenblast J, Hirth D, Eckardt A, Leinung M, Diensthuber M, Stöver T, Hambek M. Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck. Mol Clin Oncol. 2013 Mar;1(2):286-290. doi: 10.3892/mco.2012.45. Epub 2012 Nov 27. PubMed PMID: 24649162; PubMed Central PMCID: PMC3956268.
Geissler C, Hambek M, Eckardt A, Arnoldner C, Diensthuber M, Stöver T, Wagenblast J. The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft model. Oncol Rep. 2012 Sep;28(3):785-90. doi: 10.3892/or.2012.1903. Epub 2012 Jul 6. PubMed PMID: 22825751; PubMed Central PMCID: PMC3583430.
Balermpas P, Keller C, Hambek M, Wagenblast J, Seitz O, Rödel C, Weiss C. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e377-83. doi: 10.1016/j.ijrobp.2011.12.088. Epub 2012 Mar 11. PubMed PMID: 22414284.
Wagenblast J, Hirth D, Thron L, Arnoldner C, Diensthuber M, Stöver T, Hambek M. Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck. Oncol Lett. 2012 Jul;4(1):175-177. doi: 10.3892/ol.2012.700. Epub 2012 Apr 30. PubMed PMID: 22807983; PubMed Central PMCID: PMC3398357.
Geißler C, Hambek M, Leinung M, Diensthuber M, Gassner D, Stöver T, Wagenblast J. The challenge of tumor heterogeneity--different phenotypes of cancer stem cells in a head and neck squamous cell carcinoma xenograft mouse model. In Vivo. 2012 Jul-Aug;26(4):593-8. PubMed PMID: 22773573.
Eckardt A, Mörtel S, Wagenblast J, Stöver T, Hambek M. [Laryngeal reconstruction after resection of a subglottic adenocarcinoma]. Laryngorhinootologie. 2011 Mar;90(3):163-4. doi: 10.1055/s-0030-1262796. Epub 2010 Aug 26. PubMed PMID: 20799157.
Moertel S, Ackermann H, Baghi M, Eckardt A, Wagenblast J, Stöver T, Hambek M. Heterogeneity of primary site biopsies in head and neck squamous cell carcinoma. Anticancer Res. 2011 Feb;31(2):665-9. PubMed PMID: 21378353.
Schell B, Bauer RW, Lehnert T, Kerl JM, Hambek M, May A, Vogl TJ, Mack MG. Low-dose computed tomography of the paranasal sinus and facial skull using a high-pitch dual-source system--first clinical results. Eur Radiol. 2011 Jan;21(1):107-12. doi: 10.1007/s00330-010-1892-6. Epub 2010 Jul 20. PubMed PMID: 20644936.
Wagenblast J, Adunka O, Gstöttner W, Arnoldner C, Riedl N, Diensthuber M, Stöver T, Hambek M. AdOnco database - six years' experience with the documentation of clinical and scientific data on patients with head and neck cancer. In Vivo. 2010 Jul-Aug;24(4):603-6. PubMed PMID: 20668332.
Wagenblast J, Arnoldner C, Gstöttner W, Bisdas S, Mörtel S, May A, Hambek M. Does dexamethasone inhibit the antineoplastic effect of cisplatin and docetaxel in head and neck cancer cells?. Anticancer Res. 2010 Jan;30(1):123-7. PubMed PMID: 20150626.
Balermpas P, Hambek M, Seitz O, Rödel C, Weiss C. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2009 Dec;185(12):775-81. doi: 10.1007/s00066-009-2092-7. PubMed PMID: 20013086.
Wagenblast J, Baghi M, Mörtel S, Hirth D, Thron L, Arnoldner C, Gstöttner W, May A, Hambek M. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?. Oncol Rep. 2009 Jul;22(1):171-6. doi: 10.3892/or_00000421. PubMed PMID: 19513520.
Bisdas S, Rumboldt Z, Wagenblast J, Baghi M, Koh TS, Hambek M, Vogl TJ, Mack MG. Response and progression-free survival in oropharynx squamous cell carcinoma assessed by pretreatment perfusion CT: comparison with tumor volume measurements. AJNR Am J Neuroradiol. 2009 Apr;30(4):793-9. doi: 10.3174/ajnr.A1449. PubMed PMID: 19351906; PubMed Central PMCID: PMC7051758.
Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H, May A, Hambek M, Knecht R. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J Cancer Res Clin Oncol. 2009 Mar;135(3):387-93. doi: 10.1007/s00432-008-0477-0. Epub 2008 Oct 1. PubMed PMID: 18830627.
Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, May A, Knecht R, Hambek M. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity. Oncol Rep. 2008 Nov;20(5):1207-11. PubMed PMID: 18949423.
Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H, May A, Knecht R, Hambek M. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. Anticancer Res. 2008 Jul-Aug;28(4B):2239-43. PubMed PMID: 18751401.
Wagenblast J, Baghi M, Helbig M, Arnoldner C, Bisdas S, Gstöttner W, Hambek M, May A. Craniofacial reconstructions with bone-anchored epithesis in head and neck cancer patients--a valid way back to self-perception and social reintegration. Anticancer Res. 2008 Jul-Aug;28(4C):2349-52. PubMed PMID: 18751417.
Baghi M, Wagenblast J, Hambek M, Moertel S, Gstoettner W, Strebhardt K, Knecht R. Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients. Clin Otolaryngol. 2008 Jun;33(3):245-51. doi: 10.1111/j.1749-4486.2008.01702.x. PubMed PMID: 18559031.
Wagenblast J, Hambek M, Baghi M, Knecht R. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines. Anticancer Res. 2008 Mar-Apr;28(2A):687-92. PubMed PMID: 18507008.
Wagenblast J, Hambek M, Baghi M, Gstöttner W, Strebhardt K, Ackermann H, Knecht R. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol. 2008 Mar;134(3):323-30. doi: 10.1007/s00432-007-0287-9. Epub 2007 Aug 14. PubMed PMID: 17701215.
Baghi M, Bisdas S, Engels K, Yousefi M, Wagenblast J, Hambek M, Knecht R. Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer. Clin Otolaryngol. 2007 Oct;32(5):372-7. doi: 10.1111/j.1749-4486.2007.01531.x. PubMed PMID: 17883558.
Baghi M, Mack MG, Wagenblast J, Hambek M, Rieger J, Bisdas S, Gstoettner W, Engels K, Vogl T, Knecht R. Iron oxide particle-enhanced magnetic resonance imaging for detection of benign lymph nodes in the head and neck: how reliable are the results?. Anticancer Res. 2007 Sep-Oct;27(5B):3571-5. PubMed PMID: 17972519.
Hambek M, Werner C, Baghi M, Gstöttner W, Knecht R. Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation. Eur J Cancer. 2007 Jul;43(10):1502-7. doi: 10.1016/j.ejca.2005.09.037. Epub 2007 May 23. PubMed PMID: 17524637.
Baghi M, Wagenblast J, Hambek M, Radeloff A, Gstoettner W, Scherzed A, Spaenkuch B, Yuan J, Hornung S, Strebhardt K, Knecht R. Demands on caring relatives of head and neck cancer patients. Laryngoscope. 2007 Apr;117(4):712-6. doi: 10.1097/mlg.0b013e318031d0b4. PubMed PMID: 17415143.
Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, Knecht R. Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck. 2007 Mar;29(3):244-8. doi: 10.1002/hed.20503. PubMed PMID: 17123309.
Baghi M, Mack MG, Hambek M, Bisdas S, Muerthel R, Wagenblast J, Gstoettner W, Vogl T, Knecht R. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. Head Neck. 2007 Feb;29(2):104-8. doi: 10.1002/hed.20488. PubMed PMID: 17111434.
Hambek M, Werner C, Baghi M, Gstöttner W, Knecht R. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy. Anticancer Res. 2006 Mar-Apr;26(2A):1091-5. PubMed PMID: 16619511.
Hambek M, Adunka O, Baghi M, Gstoettner W, Knecht R. AdOnco: a database for clinical and scientific documentation of head and neck oncology. Ann Otol Rhinol Laryngol. 2006 Feb;115(2):144-9. doi: 10.1177/000348940611500211. PubMed PMID: 16514798.
Baghi M, Hambek M, May A, Radeloff A, Gstoettner W, Knecht R. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck. Anticancer Res. 2006 Jan-Feb;26(1B):559-63. PubMed PMID: 16739320.
Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res. 2006 Jan-Feb;26(1B):585-90. PubMed PMID: 16739325.
Hambek M, Baghi M, Strebhardt K, Baumann H, Gstöttner W, Knecht R. Reduction of cisplatin dosage by ZD 1839. Anticancer Res. 2005 Nov-Dec;25(6B):3985-8. PubMed PMID: 16309188.
Baghi M, Mack MG, Hambek M, Rieger J, Vogl T, Gstoettner W, Knecht R. The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers. Anticancer Res. 2005 Sep-Oct;25(5):3665-70. PubMed PMID: 16101198.
Schlingemann J, Habtemichael N, Ittrich C, Toedt G, Kramer H, Hambek M, Knecht R, Lichter P, Stauber R, Hahn M. Patient-based cross-platform comparison of oligonucleotide microarray expression profiles. Lab Invest. 2005 Aug;85(8):1024-39. doi: 10.1038/labinvest.3700293. PubMed PMID: 16205657.
Hambek M, Baghi M, Baumaun H, Strebhardt K, Adunka O, Gstöttner W, Knecht R. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN). Anticancer Res. 2005 May-Jun;25(3B):1871-5. PubMed PMID: 16158919.
Adunka O, Unkelbach MH, Gstöttner W, Hambek M, Knecht R. [Adonco. A clinical-scientific database system for the acquisition and analysis of oncologic data in head and neck regions]. HNO. 2005 Jan;53(1):39-45. doi: 10.1007/s00106-004-1081-5. PubMed PMID: 15064928.
Knecht R, Peters S, Hambek M, Solbach C, Baghi M, Gstöttner W, Hambek M. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Adv Otorhinolaryngol. 2005;62:81-91. doi: 10.1159/000082475. PubMed PMID: 15608420.
Hambek M, Baghi M, Strebhardt K, May A, Adunka O, Gstöttner W, Knecht R. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR. Anticancer Res. 2004 Nov-Dec;24(6):3881-6. PubMed PMID: 15736426.
Adunka O, Unkelbach MH, Mack M, Hambek M, Gstoettner W, Kiefer J. Cochlear implantation via the round window membrane minimizes trauma to cochlear structures: a histologically controlled insertion study. Acta Otolaryngol. 2004 Sep;124(7):807-12. doi: 10.1080/00016480410018179. PubMed PMID: 15370564.
Peters S, Hambek M, Gstöttner W, Knecht R. [Tissue microarrays. Value of immunohistochemical proliferation markers for serial investigations of head and neck cancer]. HNO. 2004 May;52(5):409-12. doi: 10.1007/s00106-003-0914-y. PubMed PMID: 15138646.
Adunka O, Gstoettner W, Hambek M, Unkelbach MH, Radeloff A, Kiefer J. Preservation of basal inner ear structures in cochlear implantation. ORL J Otorhinolaryngol Relat Spec. 2004;66(6):306-12. doi: 10.1159/000081887. PubMed PMID: 15668529.
Knecht R, Peters S, Solbach C, Baghi M, Gstöttner W, Hambek M. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res. 2003 Nov-Dec;23(6C):4789-95. PubMed PMID: 14981927.
Knecht R, Peters S, Adunka O, Strebhardt K, Gstoettner W, Hambek M. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res. 2003 May-Jun;23(3B):2577-83. PubMed PMID: 12894544.
Hambek M, Solbach C, Schnuerch HG, Roller M, Stegmueller M, Sterner-Kock A, Kiefer J, Knecht R. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res. 2001 Feb 1;61(3):1045-9. PubMed PMID: 11221831.
What would you like to do?
  • Page of 1